Development and application of a broad-spectrum vaccine against H5N6 avian influenza

By combining the hemagglutinin backbone of the H5 subtype influenza virus and the AS1 epitope mutant, the recombinant protein SCAS1HK5052 was constructed, which solved the problem of poor protection effect of existing vaccines and achieved a broad spectrum of multiple H5 subtype influenza virus strains Sexual protection.

CN117229370BActive Publication Date: 2024-11-01NANJING ADVANCED ACAD OF LIFE & HEALTH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210647453.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-06-08
Publication Date
2024-11-01
Estimated Expiration
2042-06-08

AI Technical Summary

Technical Problem

The existing H5 subtype highly pathogenic avian influenza vaccine cannot effectively protect the serum cross-reaction between virus strains in different subtypes and time regions, resulting in poor protection effect.

Method used

Develop a broad-spectrum vaccine for avian influenza in the H5 subtype to form a recombinant by combining the hemagglutinin backbone from the first H5 subtype influenza virus strain with the AS1 epitope mutant of the second H5 subtype influenza virus strain The protein, specifically including mutations at amino acids at positions 159 and 160, introduces the N-saccharide chain and constructs the recombinant protein SCAS1HK5052 in the hypervariable region at the outer edge of the receptor binding site.

Benefits of technology

The vaccine can induce a broad spectrum of neutralizing antibodies, effectively preventing infection of most representative strains of the 10 subclasses of the H5 subtype, and significantly improving the protective effect of the immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention provides a development and application of a broad-spectrum vaccine for H5N6 avian influenza, and specifically, provides a method for preparing a recombinant protein vaccine, an inactivated vaccine and a nucleic acid vaccine and an application thereof. Experiments show that the recombinant protein vaccine, the inactivated vaccine and the nucleic acid vaccine prepared by the method of the present invention can effectively prevent infection by avian influenza virus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to the development and application of a broad-spectrum H5N6 avian influenza vaccine. Specifically, the present invention relates to the development and application of a broad-spectrum H5N6 avian influenza vaccine based on the hemagglutinin of an H5 subtype influenza virus strain as a skeleton protein. Background Art

[0002] H5N1, H5N6 and H5N8 highly pathogenic avian influenza have infected nearly a thousand people, killing more than half of them. In 1997, a recombinant influenza virus formed by the HA of the H5N1 subtype highly pathogenic avian influenza A / goose / Guangdong / 1 / 96 (GS / GD / 1 / 96) virus strain and other genes of the H6N1 or H9N2 virus caused multiple infections. By the end of 2020, a total of 862 people were infected with H5N1 highly pathogenic avian influenza, 455 people died, and the mortality rate was 52.8%. The infected cases were distributed in 17 countries, mainly in Asia, followed by Africa. The sporadic cases of human infection with the H5 subtype highly pathogenic avian influenza now have a mortality rate of more than 50%. If the virus continues to evolve and has the ability to spread continuously and stably from person to person, it will cause a global pandemic and pose a serious threat to human health.

[0003] Vaccines are the most effective means of preventing and controlling H5 subtype highly pathogenic avian influenza epidemics. Since the large-scale spread of H5 subtype highly pathogenic avian influenza, a variety of poultry H5 subtype highly pathogenic avian influenza vaccines have been developed, including inactivated vaccines, vector vaccines and DNA vaccines. Many countries around the world, including my country, have also developed human H5 subtype highly pathogenic avian influenza reserve vaccines, including inactivated vaccines and vector vaccines. However, the H5 subtype highly pathogenic avian influenza virus has evolved into ten subtypes, among which subtypes 1, 2 and 7 are further differentiated into secondary subtypes, tertiary subtypes, etc. Multiple subtypes are prevalent at the same time and new subtypes continue to appear. The serum cross-reaction between different subtypes and even between virus strains prevalent in different times and regions of the same subtype is weak, resulting in the inability of existing poultry and human H5 subtype highly pathogenic avian influenza vaccines to provide good protection.

[0004] Therefore, there is an urgent need in the art to develop a broad-spectrum vaccine for H5 subtype avian influenza. Summary of the invention

[0005] The purpose of the present invention is to provide a broad-spectrum vaccine for H5 subtype avian influenza.

[0006] In a first aspect of the present invention, a hemagglutinin recombinant protein is provided, wherein the recombinant protein contains a hemagglutinin backbone from a first H5 subtype influenza virus strain and an AS1 epitope from a second H5 subtype influenza virus strain, wherein the AS1 epitope is an AS1 epitope mutant, wherein the AS1 epitope mutant has a mutation in amino acids selected from the group consisting of amino acids 98, 129-138, 153-161, 183, 186-194 and 221-228 (H3 numbering) in the wild-type AS1 epitope corresponding to the hemagglutinin sequence from the second H5 subtype influenza virus strain (amino acid sequence GISAID accession number: EPI533583):

[0007] Aspartic acid (Asp, D) at position 159; and

[0008] Alanine (Ala, A) at position 160;

[0009] Furthermore, the first H5 subtype influenza virus strain includes A / common magpie / Hong Kong / 5052 / 2007 (H5N1);

[0010] The second H5 subtype influenza virus strain includes A / Sichuan / 26221 / 2014 (H5N6).

[0011] In another preferred embodiment, the sequence number of the hemagglutinin backbone amino acid sequence from the first H5 subtype influenza virus strain is ACJ26242 (NCBI accession number).

[0012] In another preferred embodiment, by mutation of amino acids at positions 159 and 160, an "Asn-Ser-Thr (NST)" sequence is formed at amino acid positions 158, 159 and 160 of the recombinant protein, and an N-sugar chain is formed at the asparagine (Asparagine, Asn, N) site at position 158 of the recombinant protein, and the N-sugar chain is located in the hypervariable region at the outer edge of the receptor binding site.

[0013] In another preferred embodiment, by mutation of amino acids at positions 159 and 160, alanine (Ala, A) at position 160 is mutated to threonine (Thr, T), and aspartic acid (Asp, D) at position 159 is mutated to an amino acid other than serine and proline, forming an "Asn-X-Thr (NXT)" sequence at amino acid positions 158, 159 and 160 of the recombinant protein (X amino acid is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or a combination thereof), and an N-sugar chain is formed at the asparagine (Asn, N) site at position 158 of the recombinant protein, and the N-sugar chain is located in the hypervariable region at the outer edge of the receptor binding site.

[0014] In another preferred embodiment, by mutation of amino acids at positions 159 and 160, alanine (Ala, A) at position 160 is mutated to serine (Ser, S), and aspartic acid (Asp, D) at position 159 is mutated to an amino acid other than serine and proline, forming an "Asn-X-Ser (NXS)" sequence at amino acid positions 158, 159 and 160 of the recombinant protein (X amino acid is selected from the following group: glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or a combination thereof), and an N-sugar chain is formed at the asparagine (Asn, N) site at position 158 of the recombinant protein, and the N-sugar chain is located in the hypervariable region at the outer edge of the receptor binding site.

[0015] In another preferred embodiment, the mutation includes insertion, deletion or substitution of amino acids.

[0016] In another preferred embodiment, except for the mutations (positions 159 and 160), the remaining amino acid sequences of the AS1 epitope mutant are identical or substantially identical to the sequences shown in amino acids 98, 129-138, 153-161, 183, 186-194 and 221-228 (H3 numbering) of the wild-type AS1 epitope corresponding to the hemagglutinin sequence from the second H5 subtype influenza virus strain (amino acid sequence GISAID accession number: EPI533583).

[0017] In another preferred embodiment, the hemagglutinin backbone from the first H5 subtype influenza virus strain has a homology of at least 80% with the sequence shown in ACJ26242, preferably at least 85% or 90%, more preferably at least 95%, and most preferably at least 98% or 99%.

[0018] In another preferred embodiment, the substantially identical is that there are at most 8 (preferably 1-5, more preferably 1-3) amino acid differences, wherein the differences include amino acid substitutions, deletions or additions, and an N-sugar chain is introduced at amino acid position 158 in the AS1 epitope mutant.

[0019] In another preferred embodiment, the recombinant protein has a structure comprising formula I:

[0020] Z1-Z2(I)

[0021] In the formula, Z1 is the hemagglutinin backbone from the first H5 subtype influenza virus strain A / common magpie / Hong Kong / 5052 / 2007; Z2 is the AS1 epitope from the second H5 subtype influenza virus strain A / Sichuan / 26221 / 2014; the AS1 epitope is an AS1 epitope mutant, and the AS1 epitope mutant is a wild-type AS1 epitope corresponding to the hemagglutinin sequence from the second H5 subtype influenza virus strain (amino acid sequence GISAID accession number: EPI533583) at positions 98, 129-138, 153-161, 183, 186-194 and 221-228 amino acids (H3 numbering) selected from the following group mutated:

[0022] Aspartic acid (Asp, D) at position 159; and

[0023] Alanine (Ala, A) at position 160;

[0024] Wherein, each "-" is independently a connecting peptide or a peptide bond.

[0025] In another preferred embodiment, the recombinant protein is selected from the following group:

[0026] (A) a polypeptide having an amino acid sequence as shown in SEQ ID NO.: 1;

[0027] (B) a derived polypeptide having ≥80% homology (preferably, ≥90% homology; more preferably ≥95% homology; most preferably, ≥97% homology, such as 98% or more, 99% or more) with the amino acid sequence of SEQ ID NO.: 1, and the derived polypeptide has substantially the same function as the original polypeptide before derivatization;

[0028] (C) A derivative polypeptide formed by adding, substituting or deleting one or more amino acids (e.g., 1-10, preferably, 1-5, and more preferably, 1-3) to the amino acid sequence of the polypeptide in (A), wherein the derivative polypeptide has substantially the same function as the original polypeptide before derivatization.

[0029] In another preferred embodiment, the "substantially the same function" refers to the derivative polypeptide having an introduced N-sugar chain, which can be immunized to produce neutralizing antibodies with a broad spectrum.

[0030] In another preferred example, the amino acid sequence of the recombinant protein is shown in SEQ ID NO.1.

[0031] In another preferred embodiment, the recombinant protein is a polypeptide having an amino acid sequence as shown in SEQ ID NO.: 1, an active fragment thereof, or a conservative variant polypeptide thereof.

[0032] In another preferred embodiment, the recombinant protein has a homology of at least 80% with the sequence shown in SEQ ID NO.: 1, preferably at least 85% or 90%, more preferably at least 95%, and most preferably at least 98% or 99%.

[0033] In another preferred embodiment, the recombinant protein is an artificially synthesized or recombinant recombinant protein.

[0034] In another preferred embodiment, the recombinant protein is a recombinant protein expressed by a eukaryotic expression system.

[0035] In another preferred embodiment, the recombinant protein is a recombinant protein expressed by yeast cells.

[0036] In another preferred embodiment, the recombinant protein is a recombinant protein expressed by insect cells.

[0037] In another preferred embodiment, the recombinant protein is a chimeric protein.

[0038] In another preferred embodiment, the insect cells are selected from the following group: Sf9, Sf21, Tni, Hi5-Sf cells, or a combination thereof.

[0039] In another preferred embodiment, the yeast includes Pichia pastoris.

[0040] The second aspect of the present invention provides a vaccine polypeptide, which includes the recombinant protein described in the first aspect of the present invention.

[0041] In another preferred embodiment, the vaccine polypeptide can stimulate primates, rodents and poultry to produce neutralizing antibodies that can neutralize most of the representative strains of the 10 subtypes of the H5 subtype.

[0042] In another preferred embodiment, the neutralizing antibodies stimulated by the vaccine polypeptides can prevent infection, block viral invasion and eliminate influenza viruses in the body.

[0043] In another preferred embodiment, the vaccine polypeptide induces B cell immunity in primates, rodents and poultry.

[0044] In another preferred embodiment, the primates include humans and non-human primates.

[0045] The third aspect of the present invention provides a DNA or mRNA vaccine, which contains mRNA encoding the recombinant protein described in the first aspect of the present invention and a DNA expression vector.

[0046] In another preferred embodiment, the packaging carrier of the mRNA vaccine is protamine, nanoparticle liposome, or chemically synthesized polymer.

[0047] The fourth aspect of the present invention provides an isolated polynucleotide, which encodes the recombinant protein described in the first aspect of the present invention or the vaccine polypeptide described in the second aspect of the present invention.

[0048] The fifth aspect of the present invention provides an expression vector, which contains the polynucleotide described in the fourth aspect of the present invention.

[0049] The sixth aspect of the present invention provides a host cell, wherein the host cell contains the expression vector described in the fifth aspect of the present invention, or the polynucleotide described in the fourth aspect of the present invention is integrated into its genome.

[0050] In another preferred embodiment, the host cells include prokaryotic cells and eukaryotic cells.

[0051] In another preferred embodiment, the host cells include yeast, insect Hi5-Sf cells, Escherichia coli, monkey-derived Vero E6 cells, hamster CHO cells, and DC cells.

[0052] The seventh aspect of the present invention provides an H5 subtype influenza virus strain, the genome of which contains an exogenous recombinant protein gene sequence, wherein the recombinant protein gene sequence encodes the recombinant protein described in the first aspect of the present invention.

[0053] In another preferred embodiment, the influenza virus is H5N6 influenza virus.

[0054] The eighth aspect of the present invention provides a pharmaceutical composition, which contains the recombinant protein described in the first aspect of the present invention, the vaccine polypeptide described in the second aspect of the present invention, or the mRNA or DNA vaccine described in the third aspect of the present invention, or the polynucleotide described in the fourth aspect of the present invention, or the expression vector described in the fifth aspect of the present invention, or the host cell described in the sixth aspect of the present invention, or the virus strain described in the seventh aspect of the present invention, and a pharmaceutically acceptable carrier and / or excipient.

[0055] In another preferred embodiment, the pharmaceutical composition is a vaccine composition.

[0056] In another preferred embodiment, the vaccine composition is monovalent or multivalent.

[0057] In another preferred embodiment, the pharmaceutical composition further contains an adjuvant, preferably various aluminum adjuvants.

[0058] In another preferred embodiment, the molar or weight ratio of the recombinant protein, immune polypeptide, mRNA or DNA vaccine or virus strain, and adjuvant (such as aluminum) in the pharmaceutical composition is between 1:100, preferably between 1:40 and 1:60.

[0059] In another preferred embodiment, the pharmaceutical composition includes a single drug, a compound drug, or a synergistic drug.

[0060] In another preferred embodiment, the dosage form of the pharmaceutical composition is liquid, solid, or gel.

[0061] In another preferred embodiment, the pharmaceutical composition is administered in a manner selected from the group consisting of subcutaneous injection, intradermal injection, intramuscular injection, intravenous injection, intraperitoneal injection, microneedle injection, oral administration, or oral and nasal spraying and aerosol inhalation.

[0062] The ninth aspect of the present invention provides a vaccine composition, which contains the recombinant protein described in the first aspect of the present invention, the vaccine polypeptide described in the second aspect of the present invention, the mRNA or DNA vaccine described in the third aspect of the present invention, the polynucleotide described in the fourth aspect of the present invention, the expression vector described in the fifth aspect of the present invention, the host cell described in the sixth aspect of the present invention, or the virus strain described in the seventh aspect of the present invention, and an immunologically acceptable carrier and / or excipient.

[0063] In another preferred embodiment, the vaccine composition further contains an adjuvant.

[0064] In another preferred embodiment, the adjuvant includes: granular adjuvant and non-granular adjuvant.

[0065] In another preferred embodiment, the particulate adjuvant is selected from the following group: aluminum salts, water-in-oil emulsions, oil-in-water emulsions, nanoparticles, microparticles, liposomes, immunostimulatory complexes, or a combination thereof.

[0066] In another preferred embodiment, the non-granular adjuvant is selected from the following group: muramyl dipeptide and its derivatives, saponin, lipid A, cytokine, derived polysaccharide, bacterial toxin, microorganisms and their products such as mycobacteria (tuberculosis, BCG), bacillus brevis, Bordetella pertussis, propolis, or a combination thereof.

[0067] In another preferred embodiment, the adjuvant includes alumina, saponin, Quil A, muramyl dipeptide, mineral oil or vegetable oil, vesicle-based adjuvant, non-ionic block copolymer or DEAE dextran, cytokine.

[0068] In another preferred embodiment, the vaccine composition comprises an injectable dosage form.

[0069] The tenth aspect of the present invention provides the use of the recombinant protein described in the first aspect of the present invention, the vaccine polypeptide described in the second aspect of the present invention, the mRNA or DNA vaccine described in the third aspect of the present invention, the virus strain described in the seventh aspect of the present invention, the pharmaceutical composition described in the eighth aspect of the present invention, or the vaccine composition described in the ninth aspect of the present invention, (a) for preparing antibodies against avian influenza virus hemagglutinin; and / or (b) for preparing drugs for preventing and / or treating avian influenza virus infection or related diseases thereof.

[0070] In another preferred embodiment, the avian influenza virus includes H5 subtype avian influenza virus.

[0071] In another preferred embodiment, the avian influenza virus includes H5N6 virus.

[0072] In another preferred embodiment, the antibodies include antibodies against hemagglutinin of H5 subtype avian influenza virus.

[0073] In another preferred embodiment, the antibodies include antibodies against H5 subtype avian influenza virus.

[0074] The eleventh aspect of the present invention provides a method for preparing the recombinant protein according to the first aspect of the present invention, comprising the steps of:

[0075] (i) culturing the host cell according to the sixth aspect of the present invention under suitable conditions, thereby expressing the recombinant protein according to the first aspect of the present invention;

[0076] (ii) purifying the antigenic peptide.

[0077] In another preferred embodiment, in step (i) of the method, the transformed yeast colonies are inoculated into BMGY medium respectively, the supernatant is removed by centrifugation after cultivation, the bacteria are resuspended in BMMY medium, and induced culture is carried out at 28-30°C (preferably 29.5°C) for 36-48 hours (preferably 48 hours).

[0078] The twelfth aspect of the present invention provides a method for producing an immune response against avian influenza virus, comprising the steps of: administering to a subject in need thereof the recombinant protein described in the first aspect of the present invention, the vaccine polypeptide described in the second aspect of the present invention, the mRNA or DNA vaccine described in the third aspect of the present invention, or the virus strain described in the seventh aspect of the present invention, or the pharmaceutical composition described in the eighth aspect of the present invention, or the vaccine composition described in the ninth aspect of the present invention.

[0079] In another preferred embodiment, the subject includes a human or a non-human mammal.

[0080] In another preferred embodiment, the non-human mammal includes non-human primates (such as monkeys).

[0081] In another preferred embodiment, the method induces the production of neutralizing antibodies against H5 subtype avian influenza virus in the subject.

[0082] The thirteenth aspect of the present invention provides a treatment method, administering to a subject in need thereof the recombinant protein described in the first aspect of the present invention, the vaccine polypeptide described in the second aspect of the present invention, the mRNA or DNA vaccine described in the third aspect of the present invention, the polynucleotide described in the fourth aspect of the present invention, or the expression vector described in the fifth aspect of the present invention, or the host cell described in the sixth aspect of the present invention, or the virus strain described in the seventh aspect of the present invention, or the pharmaceutical composition described in the eighth aspect of the present invention, or the vaccine composition described in the ninth aspect of the present invention.

[0083] In another preferred embodiment, the treatment method includes gene therapy method.

[0084] In another preferred embodiment, the treatment method includes in vitro electroporation-transfected human DC cell transplantation and lymphocyte mRNA vaccine injection.

[0085] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0086] Figure 1 It is the amino acid sequence of the hemagglutinin of the A / common magpie / Hong Kong / 5052 / 2007 virus strain of the present invention.

[0087] Figure 2 Schematic diagram of the structures of the transfer vector, packaging vector and expression vector used in the preparation of influenza pseudovirus of the present invention.

[0088] Figure 3 The DNA plasmid map for constructing and expressing hemagglutinin in the present invention.

[0089] Figure 4 The spatial conformation and epitope of the hemagglutinin protein of the present invention are shown in FIG. The hemagglutinin protein is divided into a head region and a stem region. The head region has four epitopes, namely AS1, AS2, AS3 and AS4.

[0090] Figure 5 Schematic diagram of the construction of the recombinant pseudovirus with the hemagglutinin head and stem of the A / common magpie / Hong Kong / 5052 / 2007 virus strain and the recombinant pseudovirus with the hemagglutinin head and stem of the A / Thailand / (KAN-1) / 2004 virus strain in the present invention.

[0091] Figure 6 Schematic diagram of the construction of the recombinant pseudovirus with swapped hemagglutinin head epitopes of A / common magpie / Hong Kong / 5052 / 2007 virus strain and the recombinant pseudovirus with swapped hemagglutinin head epitopes of A / Thailand / (KAN-1) / 2004 virus strain in the present invention.

[0092] Figure 7 The present invention compares the amino acids in different epitopes of the hemagglutinin head of the A / common magpie / Hong Kong / 5052 / 2007 virus strain and the A / Thailand / (KAN-1) / 2004 virus strain.

[0093] Figure 8 This is a conservative analysis of the amino acids in the influenza hemagglutinin head of the present invention. DETAILED DESCRIPTION

[0094] The inventors have unexpectedly found through extensive and in-depth research that a recombinant protein comprising a hemagglutinin backbone from a first H5 subtype influenza virus strain (such as A / common magpie / Hong Kong / 5052 / 2007) and an AS1 epitope mutant (such as a mutation in amino acids at positions 159 and 160) from a second H5 subtype influenza virus strain (such as A / Sichuan / 26221 / 2014) can effectively induce broad-spectrum neutralizing antibodies, thereby effectively preventing infection by avian influenza viruses (especially representative strains of most of the 10 subclasses of the H5 subtype). On this basis, the inventors have completed the present invention.

[0095] the term

[0096] As used herein, the term "AxxB" means that the amino acid A at position xx is changed to amino acid B, for example, "D159S" means that the amino acid D at position 159 is mutated to S, and so on.

[0097] The term "H3 numbering" means that amino acids are numbered using the H3 numbering method.

[0098] Avian influenza virus

[0099] H5 subtype highly pathogenic avian influenza is a zoonotic infectious disease caused by influenza A virus of the genus influenza virus of the family Orthomyxoviridae. Hemagglutinin (HA) can induce antibodies with neutralizing activity, and these antibodies can prevent viral infection, block viral invasion and eliminate influenza viruses in the body. It is the main target protein of influenza A broad-spectrum vaccine.

[0100] In the present invention, the hemagglutinin HA of the H5N1 subtype avian influenza virus strain A / common magpie / Hong Kong / 5052 / 2007 is used as the backbone of the influenza vaccine (HA sequence is as follows Figure 1 As shown in SEQ ID NO.: 2), the epitopes recognized by the induced neutralizing antibodies are concentrated, and the key amino acids in the epitopes are located at or near the 158, 159 and 160 sites on the outer edge of the hemagglutinin receptor binding region (H3 numbering). Sites 158, 159 and 160 of influenza virus hemagglutinin and their vicinities are located on the outer edge of the receptor binding site, and the amino acids are poorly conserved, belonging to the high mutation region of hemagglutinin.

[0101] The hemagglutinin AS1 epitope of the A / common magpie / Hong Kong / 5052 / 2007 virus strain contains 39 amino acids, as shown in Table 1 (H3 numbering).

[0102] Table 1. Amino acids and numbers of AS1 epitopes of A / common magpie / Hong Kong / 5052 / 2007 virus strain

[0103]

[0104] Furthermore, in the present invention, the hemagglutinin HA of A / common magpie / Hong Kong / 5052 / 2007 is used as the backbone protein, and its AS1 epitope is replaced with the AS1 epitope of the A / Sichuan / 26221 / 2014 virus strain (AS1 epitope amino acid sequence is shown in Table 2), and the aspartic acid (Aspartic acid, Asp, D) at position 159 and the alanine (Alanine, Ala, A) at position 160 of the AS1 epitope are mutated to serine (Serine, Ser, S) and threonine (Threonine, Thr, T), respectively, to construct a recombinant protein immunogen (named SCAS1HK5052, the amino acid sequence is shown in SEQ ID NO.: 1). SCAS1HK5052 introduces an N-sugar chain at position 158 of the hypervariable region at the outer edge of the receptor binding site, which can induce broad-spectrum neutralizing antibodies.

[0105] Table 2. Amino acids and numbers of AS1 epitopes of A / Sichuan / 26221 / 2014 virus strain (please note that bold italics indicate sites where the amino acids in the AS1 epitope of A / common magpie / Hong Kong / 5052 / 2007 hemagglutinin differ from those in the AS1 epitope of A / Sichuan / 26221 / 2014)

[0106]

[0107]

[0108] The H5N6 mutant vaccine strain prepared by the present invention can neutralize most of the representative strains of the 10 subtypes of the H5 subtype (taking the viruses prevalent between 1997 and 2014 as an example, as shown in Table 3).

[0109] Table 3. Representative strains of the 10 subtypes of H5

[0110] Virus strain Subclass A / Hong Kong / 156 / 1997 0 A / Thailand / (KAN-1) / 2004 1 A / Cambodia / P0322095 / 2005 1 A / Indonesia / 5 / 2005 2.1.3.2 A / Turkey / 65596 / 2006 2.2.1 A / common magpie / Hong Kong / 5052 / 2007 2.3.2.1 A / duck / Guangdong / S1322 / 2010(R6) 2.3.2.1 A / Shenzhen / 406H / 2006 2.3.4 A / chicken / Guizhou / 4 / 2013(R8) 2.3.4.4 A / Sichuan / 26221 / 2014 2.3.4.4 A / chicken / Netherland-14015526 / 2014 2.3.4.4 A / chicken / Guangxi / 12 / 2004 2.4 A / chicken / Korea / es / 2003 2.5 A / silky chicken / Hong Kong / SF189 / 2001 3 A / goose / Guiyang / 337 / 2006 4 A / duck / Guangxi / 1378 / 2004 5 A / blackbird / Hunan / 1 / 2004 6 A / Duck / Hubei / wg / 2002 6 A / Beijing / 01 / 2003 7.1 A / chicken / Shanxi / 2 / 2006 7.2 A / chicken / Henan / 16 / 2004 8 A / goose / Shantou / 1621 / 2005 9

[0111] Recombinant protein

[0112] The present invention provides a hemagglutinin recombinant protein SCAS1HK5052, wherein the recombinant protein contains a hemagglutinin skeleton from a first H5 subtype influenza virus strain and an AS1 epitope from a second H5 subtype influenza virus strain, wherein the AS1 epitope is an AS1 epitope mutant, and wherein the AS1 epitope mutant is a wild-type AS1 epitope corresponding to a hemagglutinin sequence from a second H5 subtype influenza virus strain (amino acid sequence GISAID accession number is EPI533583, and the amino acid sequence is shown in SEQ ID NO.: 3) at positions 98, 129-138, 153-161, 183, 186-194 and 221-228 (H3 numbering) selected from the following group of amino acids mutated:

[0113] Aspartic acid (Asp, D) at position 159; and

[0114] Alanine (Ala, A) at position 160;

[0115] Furthermore, the first H5 subtype influenza virus strain of the present invention includes A / common magpie / Hong Kong / 5052 / 2007 (H5N1), and the sequence number of the hemagglutinin backbone sequence from the first H5 subtype influenza virus strain is ACJ26242 (the amino acid sequence is shown in SEQ ID NO.: 2);

[0116] Furthermore, the second H5 subtype influenza virus strain of the present invention includes A / Sichuan / 26221 / 2014 (H5N6).

[0117] A / common magpie / Hong Kong / 5052 / 2007 hemagglutinin HA sequence:

[0118] Mekivfllaivslvksdhicigyhannsteqvdtimeknvtvthaqdilekthngklcdlngvkplilkdcsvagwl lgnpmcdefinvpewsyivekanpandlcypgnfndyeelkhllsrinhfekiqiipkdswsdheaslgvssacpyqgnssffrnvvwlikkgnayptikksynntnqedllvlwgihhpndeaeqtrlyqnpttyisigtstlnqrlvpkiat rskvngqsgridffwtilkpndainfesngnfiapeyaykivkkgdstimkseveygncntrcqtpmgainssmpfhnihpltigecpkyvksnklvlatglrnspqrerrrkkrglfgaiagfieggwqgmvdgwygyhhsneqgsgyaa dkestqkaidgvtnkvnsiidkmntqfeavgrefnnlerrienlnkkmedgfldvwtynaellvlmenertldfhds nvknlydkvrlqlrdnakelgngcfefyhkcdnecmesvrngtydypqyseearlkreeisgvklesigtyqilsiystvasslvlaimvaglsswmcsngslqcrici(SEQ ID NO.: 2)

[0119] Hemagglutinin HA sequence of A / Sichuan / 26221 / 2014:

[0120] Mekivlllaivslvkgdqicigyhannsteqvdtimeknvtvthaqdilekthngklcdlngvkplilkdcsvagwl lgnpmcdefirvpewsyiveranpandlcypgnlndyeelkhllsrinhfekiliipksswtnhetslgvsaacpyqgtpsffrnvvwlikkndayptikisynntnqedllilwgvhhsnnaaeqtnlyknpttyisvgtstlnqrlvpkiatrs qvngqrgrmdffwtilkpndaihfesngnfiapeyaykivkkgdstimksemeyghcntkcqtpigainssmpfhnihpltigecpkyvksnklvlatglrnsplrekrrkrglfgaiagfieggwqgmvdgwygyhhsneqgsgyaad kestqkaidgvtnkvnsiidkmntqfeavgrefnnlerrienlnkkmedgfldvwtynaellvlmenertldfhdsnvknlydkvrlqlrdnakelgngcfefyhkcdnkcmesvrngtydypqyseearlkreeisgvklesigtyqilsiyst vasslalaiivaglslwmcsngslqcrici(SEQ ID NO.:3)

[0121] In the present invention, by mutation of amino acids at positions 159 and 160, an "Asn-Ser-Thr (NST)" sequence is formed at amino acids at positions 158, 159 and 160 of the recombinant protein, and an N-sugar chain is formed at the asparagine (Asparagine, Asn, N) site at position 158 of the recombinant protein, and the N-sugar chain is located in the hypervariable region at the outer edge of the receptor binding site.

[0122] It should be understood that the amino acid numbers in the A / common magpie / Hong Kong / 5052 / 2007 hemagglutinin HA sequence (SEQ ID NO.: 2), the A / Sichuan / 26221 / 2014 hemagglutinin HA sequence (SEQ ID NO.: 3) and the recombinant protein SCAS1HK5052 (SEQ ID NO.: 1) of the present invention are all based on a unified H3 numbering method, which facilitates accurate identification of AS1 epitope amino acid sites and mutated amino acid sites, and can also avoid sequence homology differences caused by amino acid number misalignment caused by conventional sequence comparison techniques.

[0123] Amino acid sequence of recombinant protein SCAS1HK5052:

[0124] Mekivllfaivslvksdhicigyhannsteqvdtimeknvtvthaqdilekthngklcdlngvkplilkdcsv agwllgnpmcdefinvpewsyivekanpandlcypgnfndyeelkhllsrinhfekiqiipkdswsnhetslgvsaacpyqgnssffrnvvwlikknstyptikksynntnqedllvlwgihhpnnaaeqtnlyqnpttyisigtstlnqrlvp kiatrsqvngqrgridffwtilkpndainfesngnfiapeyaykivkkgdstimkseveygncntrcqtpmgainssmpfhnihpltigecpkyvksnklvlatglrnspqrerrrkrglfgaiagfieggwqgmvdgwygyhhsneqgsgy aadkestqkaidgvtnkvnsiidkmntqfeavgrefnnlerrienlnkkmedgfldvwtynaellvlmenertldfh dsnvknlydkvrlqlrdnakelgngcfefyhkcdnecmesvrngtydypqyseearlkreeisgvklesigtyqilsiystvasslvlaimvaglsswmcsngslqcrici(SEQ ID NO.:1)

[0125] The recombinant protein SCAS1HK5052 (SEQ ID NO.: 1) of the present invention is a synthetic protein or a recombinant protein, that is, it can be a product of chemical synthesis, or produced from a prokaryotic or eukaryotic host (e.g., bacteria, yeast, plants) using recombinant technology. The recombinant protein of the present invention may also include or not include an initial methionine residue.

[0126] The present invention also includes fragments, derivatives and analogs of the recombinant protein. As used herein, the terms "fragment", "derivative" and "analog" refer to proteins that substantially retain the same biological function or activity of the recombinant protein.

[0127] The recombinant protein fragments, derivatives or analogs of the present invention can be

[0128] (i) a recombinant protein having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) a recombinant protein having a substituent group in one or more amino acid residues, or (iii) a recombinant protein formed by fusion of a mature recombinant protein with another compound (such as a compound that prolongs the half-life of a mutant protein, such as polyethylene glycol), or (iv) a recombinant protein formed by fusion of an additional amino acid sequence to the recombinant protein sequence (such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the recombinant protein, or a fusion protein formed with an antigen IgG fragment). According to the teachings of this article, these fragments, derivatives and analogs belong to the scope known to those skilled in the art. In the present invention, the conservatively substituted amino acids are preferably produced by amino acid substitution according to Table 4.

[0129] Table 4

[0130] Initial residue Representative replacement Preferred substitutions Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Lys; Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro; Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu; Val; Met; Ala; Phe Leu Leu(L) Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu Phe(F) Leu; Val; Ile; Ala; Tyr Leu Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr; Phe Tyr Tyr(Y) Trp; Phe; Thr; Ser Phe Val(V) Ile; Leu; Met; Phe; Ala Leu

[0131] The active recombinant protein of the present invention has substantially the same immunogenicity for stimulating immune response, and the induced neutralizing antibody has the activity of neutralizing most representative strains of 10 subclasses of the H5 subtype.

[0132] Preferably, the recombinant protein is SCAS1HK5052, as shown in SEQ ID NO.:1.

[0133] It should be understood that the recombinant protein of the present invention has a higher homology (identity) than the sequence shown in SEQ ID NO.: 1. Preferably, the recombinant protein has a homology of at least 80% with the sequence shown in SEQ ID NO.: 1, preferably at least 85%-90%, more preferably at least 95%, optimally at least 98%, and optimally ≥99%.

[0134] In addition, the recombinant protein of the present invention can also be modified. Modifications (usually without changing the primary structure) include: chemical derivatization of recombinant proteins in vivo or in vitro, such as acetylation or carboxylation. Modifications also include glycosylation, such as those produced by glycosylation modification during the synthesis and processing of recombinant proteins or in further processing steps. This modification can be accomplished by exposing the recombinant protein to an enzyme that performs glycosylation (such as a mammalian glycosylase or deglycosylation enzyme). Modified forms also include sequences with phosphorylated amino acid residues (such as phosphotyrosine, phosphoserine, phosphothreonine). Also included are recombinant proteins that have been modified to improve their resistance to proteolysis or optimize their solubility.

[0135] The term "polynucleotide encoding a recombinant protein" may include a polynucleotide encoding the recombinant protein of the present invention, or may include a polynucleotide further including additional coding and / or non-coding sequences; nucleotides include ribonucleic acid (RNA) and deoxyribonucleic acid (DNA).

[0136] The present invention also relates to variants of the above-mentioned polynucleotides, which encode fragments, analogs and derivatives of polypeptides or recombinant proteins having the same amino acid sequence as the present invention. These nucleotide variants include substitution variants, deletion variants and insertion variants. As known in the art, an allelic variant is a replacement form of a polynucleotide, which may be a substitution, deletion or insertion of one or more nucleotides, but will not substantially change the function of the recombinant protein encoded by it.

[0137] The present invention also relates to polynucleotides that hybridize with the above-mentioned sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that can hybridize with the polynucleotides described in the present invention under stringent conditions (or stringent conditions). In the present invention, "stringent conditions" refer to: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) the addition of denaturing agents during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, preferably 95%.

[0138] The recombinant proteins and polynucleotides of the present invention are preferably provided in an isolated form, and more preferably, purified to homogeneity.

[0139] The full-length sequence of the polynucleotide of the present invention can usually be obtained by PCR amplification, recombination or artificial synthesis. For PCR amplification, primers can be designed based on the relevant nucleotide sequences disclosed in the present invention, especially the open reading frame sequences, and commercially available cDNA libraries or cDNA libraries prepared by conventional methods known to those skilled in the art are used as templates to amplify and obtain the relevant sequences. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then splice the fragments amplified in each time together in the correct order.

[0140] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the propagated host cells by conventional methods.

[0141] In addition, artificial synthesis methods can also be used to synthesize related sequences, especially when the fragment length is shorter. Usually, a long fragment of sequence can be obtained by synthesizing multiple small fragments first and then connecting them.

[0142] At present, the DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequence of the present invention by chemical synthesis.

[0143] The method of amplifying DNA / RNA using PCR technology is preferably used to obtain the polynucleotide of the present invention. In particular, when it is difficult to obtain full-length cDNA from a library, the RACE method (RACE-cDNA terminal rapid amplification method) can be preferably used. The primers used for PCR can be appropriately selected based on the sequence information of the present invention disclosed herein, and can be synthesized by conventional methods. The amplified DNA / RNA fragments can be separated and purified by conventional methods such as by gel electrophoresis.

[0144] Vaccine peptides

[0145] In the present invention, "epitope peptide of the present invention", "vaccine polypeptide of the present invention" and "polypeptide of the present invention" are used interchangeably and refer to the vaccine polypeptide described in the second aspect of the present invention.

[0146] In the present invention, the vaccine polypeptide also includes other forms, such as pharmaceutically acceptable salts, conjugates, or fusion proteins.

[0147] In the present invention, the vaccine polypeptide includes a derivative polypeptide formed by adding one or more (such as 1-5, preferably 1-3) amino acids, replacing one or more (such as 1-5, preferably 1-3) amino acids and / or deleting 1-3 amino acids to the sequence shown in SEQ ID NO.: 1, and the derivative polypeptide has basically the same function as the original polypeptide before derivatization.

[0148] Preferably, the vaccine polypeptide comprises 1-3 amino acids added to the sequence shown in SEQ ID NO.: 1 (preferably added to the N-terminus or C-terminus), and / or 1-2 amino acids substituted (preferably conservative amino acid substitutions) and still has basically the same function as the original polypeptide before derivatization.

[0149] Preferably, the conservative amino acid substitutions are performed according to Table 5.

[0150] Table 5

[0151] Initial residue Representative replacement Preferred substitutions Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Lys; Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro; Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu; Val; Met; Ala; Phe Leu Leu(L) Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu Phe(F) Leu; Val; Ile; Ala; Tyr Leu Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr; Phe Tyr Tyr(Y) Trp; Phe; Thr; Ser Phe Val(V) Ile; Leu; Met; Phe; Ala Leu

[0152] As used herein, "isolated" means that a substance is separated from its original environment (if it is a natural substance, the original environment is the natural environment). For example, a polypeptide in its natural state in a living cell is not isolated and purified, but the same polypeptide is isolated and purified if it is separated from other substances that exist with it in its natural state.

[0153] As used herein, "isolated peptide" means that the polypeptide of the present invention is substantially free of other proteins, lipids, carbohydrates or other substances naturally associated therewith. Those skilled in the art can purify the polypeptide of the present invention using standard protein purification techniques. Substantially purified polypeptides (fusion proteins) can produce a single main band on a non-reducing polyacrylamide gel.

[0154] The polypeptide of the present invention may be a recombinant polypeptide or a synthetic polypeptide, preferably a synthetic polypeptide.

[0155] In the present invention, when the sequence of the vaccine polypeptide is relatively short (eg, ≤70 aa, more preferably ≤60 aa), the relevant peptide sequence can be directly synthesized by chemical methods.

[0156] When the sequence of the vaccine polypeptide is long or provided in the form of a fusion protein, the relevant peptide sequence can also be obtained in large quantities by recombinant methods. This is usually done by cloning the coding sequence encoding the antigenic polypeptide or its fusion protein into a vector, then transferring it into cells, and then isolating the relevant antigenic peptide or fusion protein from the proliferated host cells by conventional methods.

[0157] mRNA vaccine, DNA vaccine or VLPs vaccine

[0158] The present invention also provides an mRNA vaccine, a DNA vaccine or a VLPs vaccine for preventing H5 subtype avian influenza virus.

[0159] mRNA vaccine is an RNA with translation activity prepared in vitro, and its main structure includes 5'UTR and 3'UTR and an open reading frame containing the recombinant protein SCAS1HK5052 (SEQ ID NO.: 1) of the present invention. Compared with DNA vaccines, it does not need to enter the cell nucleus and has no risk of integration into the genome. Typically, the method of mRNA vaccine includes: according to the amino acid sequence of SCAS1HK5052 (SEQ ID NO.: 1), a template is constructed by PCR method or artificial synthesis method and in vitro transcription is obtained to obtain the initial mRNA product, and further capping, tailing, etc. are added to obtain a structurally complete mRNA, which enters the body through a delivery system.

[0160] DNA vaccine is a recombinant eukaryotic expression vector containing an open reading frame of the SCAS1HK5052 (SEQ ID NO.: 1) protein. The exogenous SCAS1HK5052 (SEQ ID NO.: 1) gene can be transcribed, translated and expressed in living cells, inducing specific humoral and cellular immune responses. The DNA sequence encodes only a single protein gene, which is basically not likely to be toxic and is an injectable DNA molecule. Typically, the method of DNA vaccine includes: constructing a template sequence according to the amino acid sequence of the recombinant protein SCAS1HK5052 (SEQ ID NO.: 1) by PCR method or artificial synthesis method, and connecting the sequence to the target vector to form a DNA vaccine that can be taken up by host cells and transcribed and translated in vivo to express the corresponding SCAS1HK5052 recombinant protein (SEQ ID NO.: 1).

[0161] VLPs (virus-like particles) are virus-like particles that do not contain viral nucleic acid. They are similar to natural virus particles in morphology and structure, but are not infectious. They have strong immunogenicity and biological activity. They are safe and highly effective. Typically, the method of VLPs vaccine includes: containing a gene expression vector plasmid encoding the recombinant protein SCAS1HK5052 (SEQ ID NO.: 1), a gene expression vector encoding A / Sichuan / 26221 / 2014 ceramide (NA), a transfer vector plasmid and a packaging vector plasmid, and co-transfecting cells to obtain.

[0162] It should be understood that an amino acid may have multiple bases, and the nucleotide sequence corresponding to the recombinant protein SCAS1HK5052 (SEQ ID NO.: 1) may be many, but the mRNA vaccine, DNA vaccine and expression vector containing the coding sequence of the recombinant protein SCAS1HK5052 (SEQ ID NO.: 1) finally translate and express the protein amino acid sequence in vivo to be consistent with the amino acid sequence of SCAS1HK5052 (SEQ ID NO.: 1), or the homology is at least 80%, preferably at least 85%-90%, more preferably at least 95%, optimally at least 98%, and optimally ≥99%. And the corresponding translated protein AS1 epitope has an N-sugar chain introduced.

[0163] Inactivated or attenuated vaccines

[0164] The invention also provides an inactivated vaccine for preventing H5 subtype avian influenza virus.

[0165] Inactivated vaccines are vaccines that are made by culturing viruses or bacteria and then inactivating them using physical (such as heating) or chemical agents (such as β-propiolactone) to make them lose their infectivity or toxicity, but still retain their immunogenicity. Inactivated vaccines can be composed of whole viruses or bacteria, or composed of their cleaved fragments as cleaved vaccines, which are further purified until the vaccine contains only the desired antigenic components. Attenuated vaccines are vaccines that have undergone various treatments to reduce the toxicity of pathogenic microorganisms, but still retain their immunogenicity.

[0166] Typically, the method of inactivated vaccine and attenuated vaccine includes obtaining avian influenza virus by co-transfecting cells with plasmids according to the nucleotide sequence of H5 subtype avian influenza virus using reverse genetic technology, and further inactivating or treating the virus after virus amplification by cells or chicken embryos, so that the infectivity (or toxicity) of the virus is lost or weakened. It should be understood that in a preferred embodiment of the present invention, the hemagglutinin protein of influenza virus obtained by reverse genetic technology is a recombinant protein, and the amino acid sequence is consistent with the amino acid sequence of SCAS1HK5052 (SEQ ID NO.: 1), or the homology is at least 80%, preferably at least 85%-90%, more preferably at least 95%, optimally at least 98%, and optimally ≥99%. And the corresponding translated protein AS1 epitope has an N-sugar chain introduced.

[0167] Vectors and host cells

[0168] The present invention also provides a vector comprising the recombinant protein coding sequence of the present invention, and a host cell containing the vector.

[0169] In a preferred example of the present invention, the vector has an expression cassette for expressing the recombinant protein gene, and the expression cassette has the following elements in order from 5' to 3': a promoter, a recombinant protein gene, and a terminator.

[0170] The above-mentioned optimized gene sequence of the recombinant protein can be obtained by conventional methods that can be used by those of ordinary skill in the art, such as full artificial synthesis or PCR synthesis. A preferred synthesis method is asymmetric PCR. The primers used for PCR can be appropriately selected according to the sequence information of the present invention disclosed herein, and can be synthesized by conventional methods. Conventional methods can be used, such as separation and purification of amplified DNA / RNA fragments by gel electrophoresis.

[0171] The polynucleotide sequence of the present invention can be used to express or produce a target protein (recombinant protein) by conventional recombinant DNA technology, comprising the steps of:

[0172] (1) Transform or transduce a suitable host cell, preferably yeast, with a polynucleotide (or variant) encoding the protein of the present invention, or with a recombinant expression vector containing the polynucleotide.

[0173] (2) culturing host cells in a suitable culture medium;

[0174] (3) Isolate and purify proteins from culture medium or cells.

[0175] Methods well known to those skilled in the art can be used to construct expression vectors containing the coding DNA sequence of the protein of the present invention and suitable transcription / translation control signals, preferably commercially available vectors such as pPinkαHC or pMT / BiP / V5-HisA. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. The DNA sequence can be effectively connected to a suitable promoter in the expression vector to guide mRNA synthesis. The expression vector also includes a ribosome binding site and a transcription terminator for translation initiation. In addition, the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selecting transformed host cells.

[0176] The vector containing the above DNA sequence and an appropriate promoter or control sequence can be used to transform appropriate host cells to express the target protein. The host cell capable of expressing the recombinant protein of the present invention can be a prokaryotic cell, such as Escherichia coli; or a lower eukaryotic cell, such as a yeast cell (Pichia pastoris, Saccharomyces cerevisiae); or a higher eukaryotic cell, such as an insect cell; preferably a yeast cell. Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. The engineered cell can be a fast methanol-utilizing type (Mut + ) or slow methanol utilization type (Mut s ).

[0177] Cultivation of engineered cells and fermentation production of target proteins

[0178] After obtaining the engineered cells, the engineered cells can be cultured under suitable conditions to express the protein encoded by the gene sequence of the present invention. Depending on the host cells, the culture medium used in the culture can be selected from various conventional culture media, and culture is carried out under conditions suitable for the growth of the host cells. When the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.

[0179] In the present invention, conventional fermentation conditions can be used. Representative conditions include (but are not limited to):

[0180] (a) In terms of temperature, the fermentation and induction temperature of the recombinant protein of the present invention is maintained at 28-30°C;

[0181] (b) With regard to the pH value during the induction period, the pH value during the induction period is controlled at 3-9;

[0182] (c) As for dissolved oxygen (DO), DO is controlled at 20-90%. The maintenance of dissolved oxygen can be solved by introducing oxygen / air mixed gas;

[0183] (d) As for feed supplementation, feed supplementation types preferably include carbon sources such as glycerol, methanol, glucose, etc., which can be supplemented individually or in combination.

[0184] The target protein expressed by engineered cells can be purified by chromatography technology. Chromatography technology includes cation exchange chromatography, anion exchange chromatography, gel filtration chromatography, hydrophobic chromatography, affinity chromatography and other technologies. Commonly used chromatography methods include:

[0185] 1. Anion Exchange Chromatography

[0186] Anion exchange chromatography media include (but are not limited to): Q-Sepharose, DEAE-Sepharose. If the salt concentration of the fermentation sample is high and affects the binding with the ion exchange medium, the salt concentration needs to be reduced before ion exchange chromatography. The sample can be replaced with the equilibrium buffer by dilution, ultrafiltration, dialysis, gel filtration chromatography, etc. until it is similar to the corresponding ion exchange column equilibrium liquid system, and then loaded and subjected to gradient elution of salt concentration or pH.

[0187] 2. Hydrophobic chromatography

[0188] Hydrophobic chromatography media include (but are not limited to): Phenyl-Sepharose, Butyl-Sepharose, Octyle-Sepharose. The sample was added with NaCl, (NH 4 ) 2 SO4 The salt concentration is increased by other methods, and then the sample is loaded and eluted by reducing the salt concentration. Impure proteins with large differences in hydrophobicity are removed by hydrophobic chromatography.

[0189] 3. Gel Filtration Chromatography

[0190] Hydrophobic chromatography media include (but are not limited to): Sephacryl, Superdex, Sephadex, etc. The buffer system can be replaced or further purified by gel filtration chromatography.

[0191] 4. Affinity chromatography

[0192] Affinity chromatography media include (but are not limited to): HiTrap TM Heparin HP Columns.

[0193] Preparation method

[0194] The recombinant protein (polypeptide) of the present invention can be a recombinant polypeptide or a synthetic polypeptide. The polypeptide of the present invention can be chemically synthesized or recombinant. Accordingly, the polypeptide of the present invention can be artificially synthesized by conventional methods or produced by recombinant methods.

[0195] A preferred method is to use liquid phase synthesis technology or solid phase synthesis technology, such as Boc solid phase method, Fmoc solid phase method or a combination of the two methods. Solid phase synthesis can quickly obtain samples, and appropriate resin carriers and synthesis systems can be selected according to the sequence characteristics of the target peptide. For example, the preferred solid phase carrier in the Fmoc system is Wang resin connected to the C-terminal amino acid in the peptide. The Wang resin structure is polystyrene, and the arm between the amino acid is 4-alkoxybenzyl alcohol; it is treated with 25% hexahydropyridine / dimethylformamide at room temperature for 20 minutes to remove the Fmoc protecting group, and extend from the C-terminus to the N-terminus one by one according to the given amino acid sequence. After the synthesis is completed, the synthesized proinsulin-related peptide is cut from the resin with trifluoroacetic acid containing 4% p-methylphenol and the protecting group is removed. The crude peptide can be separated by ether precipitation after filtering the resin. After the solution of the obtained product is freeze-dried, the desired peptide is purified by gel filtration and reversed-phase high-pressure liquid chromatography. When using the Boc system for solid phase synthesis, the preferred resin is a PAM resin connected to the C-terminal amino acid in the peptide. The PAM resin structure is polystyrene, and the arm between the amino acid is 4-hydroxymethylphenylacetamide. In the Boc synthesis system, in the cycle of deprotection, neutralization, and coupling, TFA / dichloromethane (DCM) is used to remove the protective group Boc and diisopropylethylamine (DIEA / dichloromethane is used for neutralization. After the peptide chain condensation is completed, it is treated with hydrogen fluoride (HF) containing p-cresol (5-10%) at 0°C for 1 hour to cut the peptide chain from the resin and remove the protective group at the same time. The peptide is extracted with 50-80% acetic acid (containing a small amount of mercaptoethanol), and the solution is lyophilized and further treated with molecular sieve Sephadex G10 or Tsk-40f is separated and purified, and then purified by high pressure liquid phase to obtain the desired peptide. Various coupling agents and coupling methods known in the field of peptide chemistry can be used to couple the amino acid residues, for example, dicyclohexylcarbodiimide (DCC), hydroxybenzotriazole (HOBt) or 1,1,3,3-tetraurea hexafluorophosphate (HBTU) can be used for direct coupling. For the synthesized short peptide, its purity and structure can be confirmed by reverse phase high performance liquid chromatography and mass spectrometry analysis.

[0196] In one embodiment, the recombinant protein of the present invention is prepared according to its sequence by solid phase synthesis, purified by high performance liquid chromatography to obtain a high purity target peptide lyophilized powder, and stored at -20°C.

[0197] Another method is to use recombinant technology to produce the polypeptide of the present invention. The polynucleotide of the present invention can be used to express or produce the antigenic peptide of the present invention through conventional recombinant DNA technology. Generally speaking, there are the following steps:

[0198] (1) Transforming or transducing a suitable host cell with a polynucleotide (or variant) of the recombinant protein of the present invention, or a recombinant expression vector containing the polynucleotide;

[0199] (2) Host cells cultured in a suitable culture medium;

[0200] (3) Isolate and purify proteins from culture medium or cells.

[0201] The recombinant polypeptide can be expressed in the cell, on the cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.

[0202] Since the polypeptide of the present invention is relatively short, it is possible to consider connecting multiple polypeptides in series, obtaining a polymeric expression product after recombinant expression, and then forming the desired small peptide by methods such as enzyme cleavage.

[0203] Preparation of vaccine compositions

[0204] The present invention also provides a method for preparing a vaccine composition, specifically, comprising the steps of:

[0205] The recombinant protein prepared by the present invention is mixed with a pharmaceutically acceptable vaccine adjuvant to form a vaccine composition.

[0206] In another preferred embodiment, the adjuvant is an aluminum adjuvant or a GLA adjuvant, preferably an aluminum adjuvant.

[0207] Compositions and methods of administration

[0208] The present invention also provides a composition, which contains: (i) a recombinant protein or vaccine polypeptide prepared by the method of the present invention, and (ii) a pharmaceutically or immunologically acceptable excipient or adjuvant. In the present invention, the term "comprising" means that various components can be applied to or present in the composition of the present invention together. Therefore, the terms "mainly consisting of" and "consisting of" are included in the term "comprising".

[0209] The composition of the present invention includes a pharmaceutical composition and a vaccine composition. The composition of the present invention can be monovalent or multivalent.

[0210] The pharmaceutical composition or vaccine composition of the present invention can be prepared into various conventional dosage forms, including (but not limited to): injections, granules, tablets, pills, suppositories, capsules, suspensions, sprays, etc.

[0211] (i) Pharmaceutical Compositions

[0212] The pharmaceutical composition of the present invention comprises an effective amount of a recombinant protein or vaccine polypeptide prepared by the method of the present invention, and the recombinant protein or vaccine polypeptide may be monovalent or multivalent.

[0213] The term "effective amount" as used herein refers to the amount of a therapeutic agent that treats, alleviates or prevents a target disease or condition, or an amount that exhibits a detectable therapeutic or preventive effect. The effect can be detected, for example, by antigen levels. The therapeutic effect also includes a reduction in physiological symptoms. The exact effective amount for a subject depends on the subject's size and health, the nature and extent of the condition, and the therapeutic agent and / or combination of therapeutic agents selected for administration. Therefore, it is useless to specify an exact effective amount in advance. However, for a given condition, the effective amount can be determined by routine experiments.

[0214] For purposes of the present invention, an effective dosage is about 0.2 μg / kg to 2 μg / kg administered to a subject.

[0215] The pharmaceutical composition may also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier used for the administration of a therapeutic agent (e.g., a recombinant protein or other therapeutic agent). The term refers to such pharmaceutical carriers: they do not induce the production of antibodies harmful to the individual receiving the composition, and there is no excessive toxicity after administration. Suitable carriers can be large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acid, polyglycolic acid, etc. These carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable carriers or excipients can be found in Remington's Pharmaceutical Sciences (Mack Pub. Co., NJ 1991).

[0216] The pharmaceutically acceptable carrier in the composition may include liquids such as water, saline, glycerol and ethanol. In addition, auxiliary substances such as wetting agents or emulsifiers, pH buffer substances, etc. may also be present in these carriers. Generally, the composition can be made into an injectable, such as a liquid solution or suspension; it can also be made into a solid form suitable for mixing with a solution or suspension, a liquid excipient before injection. Liposomes are also included in the definition of pharmaceutically acceptable carriers.

[0217] (ii) Vaccine composition

[0218] The vaccine composition of the present invention can be preventive (i.e., preventing infection) or therapeutic. The vaccine composition comprises an immunogenic antigen (including a protein of the present invention or a self-assembled virus-like particle) and is usually combined with a "pharmaceutically acceptable carrier", which includes any carrier that does not induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are usually large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acid, polyglycolic acid, amino acid polymers, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), etc. These carriers are well known to those of ordinary skill in the art. In addition, these carriers can act as immunostimulants ("adjuvants"). In addition, antigens can also be coupled to bacterial toxoids (such as toxoids of pathogens such as diphtheria, tetanus, cholera, Helicobacter pylori, etc.).

[0219] Preferred adjuvants for enhancing the effect of the immunogenic composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.; (2) oil-in-water emulsion formulations, for example, (a) MF59 (see WO 90 / 14837), (b) SAF, and (c) Ribi TM Adjuvant system (RAS) (Ribi Immunochem, Hamilton, MT), (3) saponin adjuvant; (4) Freund's complete adjuvant (CFA) and Freund's incomplete adjuvant (IFA); (5) cytokines, such as interleukins (such as IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (such as gamma interferon), macrophage colony stimulating factor (M-CFS), tumor necrosis factor (TNF), etc.; (6) detoxified variants of bacterial ADP-ribosylating toxins (such as cholera toxin CT, pertussis toxin PT or Escherichia coli heat-labile toxin LT), see for example WO93 / 13302 and WO92 / 19265; and (7) other substances that act as immunostimulants to enhance the effect of the composition.

[0220] Vaccine compositions, including immunogenic compositions (e.g., may include antigens, pharmaceutically acceptable carriers and adjuvants), typically contain diluents such as water, saline, glycerol, ethanol, etc. In addition, auxiliary substances, such as wetting agents or emulsifiers, pH buffering substances, etc. may be present in such carriers.

[0221] More specifically, vaccines, including immunogenic compositions, contain an immunogenic polypeptide in an immunologically effective amount, as well as the other required components described above. An "immunologically effective amount" refers to an amount that is effective for treatment or prevention when given to an individual as a single dose or as part of a continuous dose. The amount can be determined based on the health and physiological condition of the individual being treated, the type of individual being treated (such as a human), the ability of the individual's immune system to synthesize antibodies, the degree of protection required, the formulation of the vaccine, the evaluation of the medical condition by the treating physician, and other relevant factors. It is expected that the amount will be within a relatively wide range and can be determined by routine experiments.

[0222] Typically, the vaccine composition or immunogenic composition can be prepared as an injectable, such as a liquid solution or suspension; it can also be prepared as a solid form suitable for being mixed with a solution or suspension or a liquid excipient before injection. The preparation can also be emulsified or encapsulated in a liposome to enhance the adjuvant effect.

[0223] (iii) Route of administration and dosage

[0224] The composition can be directly administered to a subject. The subject can be a human or non-human mammal, preferably a human. When used as a vaccine, the virus-like particles of the present invention can be directly administered to an individual using known methods. These vaccines are usually administered using the same administration routes as conventional vaccines and / or simulated pathogen infection routes.

[0225] The routes of administration of the pharmaceutical composition or vaccine composition of the present invention include (but are not limited to): intramuscular, subcutaneous, intradermal, intrapulmonary, intravenous, nasal, vaginal, oral or other parenteral routes of administration. If necessary, the routes of administration can be combined or adjusted according to the disease condition. The vaccine composition can be administered in a single dose or multiple doses, and can include the administration of booster doses to induce and / or maintain immunity.

[0226] Virus-like particle vaccines should be administered in an "effective amount", that is, the amount of virus-like particles is sufficient to induce an immune response in the selected administration route and can effectively protect the host against new coronavirus infection.

[0227] The amount of virus-like particles selected in each vaccine dose is determined by the amount that can induce an immune protective response without obvious side effects. Usually, after infecting host cells, each dose of vaccine is sufficient to contain about 1μg-1000μg, preferably 1μg-100μg, and more preferably 10μg-50μg protein or VLP. Standard research methods including observing antibody titers and other reactions in subjects can be used to determine the optimal dosage of a specific vaccine. The need for a booster dose can be determined by monitoring the level of immunity provided by the vaccine. After evaluating the antibody titer in the serum, it may be necessary to select a booster dose for immunization. The administration of adjuvants and / or immunostimulants can increase the immune response to the protein of the present invention. The preferred method is to administer the immunogenic composition by injection from a parenteral (subcutaneous or intramuscular) route.

[0228] The main advantages of the present invention are:

[0229] (1) The present invention first discovered that a recombinant protein comprising a hemagglutinin backbone from a first H5 subtype influenza virus strain (e.g., A / common magpie / Hong Kong / 5052 / 2007) and an AS1 epitope mutant (e.g., amino acids at positions 159 and 160 mutated, H3 numbering method) from a second H5 subtype influenza virus strain (e.g., A / Sichuan / 26221 / 2014) can effectively induce broad-spectrum neutralizing antibodies, thereby effectively preventing infection by avian influenza virus (especially representative strains of most of the 10 subtypes of the H5 subtype).

[0230] (2) The present invention selects for the first time the hemagglutinin of the H5N1 subtype avian influenza virus strain A / common magpie / Hong Kong / 5052 / 2007 as the backbone protein (recognizing only a single epitope: AS1), transfers the AS1 epitope of the A / Sichuan / 26221 / 2014 virus strain to the hemagglutinin protein of A / common magpie / Hong Kong / 5052 / 2007, replaces the original AS1 epitope, and mutates the aspartic acid (Asp, D) at position 159 and the alanine (Ala, A) at position 160 of the AS1 epitope to serine (Ser, S) and threonine (Thr, T), respectively, so that an N-sugar chain is introduced into the hypervariable region at the outer edge of the receptor binding site, thereby exposing the conserved epitope and inducing a broad-spectrum neutralizing antibody.

[0231] (3) The present invention is the first to develop a method for preparing a broad-spectrum vaccine for H5 subtype avian influenza. The H5N6 mutant vaccine strain prepared by the present invention can neutralize most of the representative strains of the 10 subtypes of the H5 subtype (especially the representative strains prevalent between 1997 and 2014).

[0232] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are generally performed under conventional conditions, such as Sambrook et al., Molecular Cloning Laboratory Guide (New York: Cold Spring Harbor Laboratory Press, 1989); or under conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0233] Unless otherwise specified, the experimental materials and reagents used in the following examples can be obtained from commercial channels.

[0234] The hemagglutinin sequence of A / common magpie / Hong Kong / 5052 / 2007 is derived from the sequence with NCBI accession number ACJ26242, the amino acid sequence of the AS1 site of A / Sichuan / 26221 / 2014 (or the amino acid sequence containing the AS1 site) is derived from the sequence with GISAID accession number EPI533583, and the recombinant protein in the method of the present invention is obtained by artificial synthesis to express the nucleotide sequence. The pseudoviruses of representative strains of 10 subclasses of the H5 subtype used in the present invention and the HA recombinant pseudoviruses were obtained from the Shanghai Pasteur Institute of the Chinese Academy of Sciences.

[0235] 1. Materials

[0236] Cell model

[0237] HEK293FT cells are human kidney epithelial cells transfected with adenovirus E1A gene and simultaneously expressing SV40 large T antigen (Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008 USA) and were used for pseudovirus and recombinant influenza virus preparation and protein expression.

[0238] MDCK cells: canine kidney cells (American Type Culture Collection, ATCC), used for pseudovirus neutralization experiments.

[0239] The mycoplasma test of the cells used in the experiment was negative. The cell culture conditions were: 37°C, 5% CO 2 .

[0240] Animal models

[0241] 6-8 week old female BALB / c mice (Shanghai Lingchang Biotechnology Co., Ltd., SPF grade).

[0242] 1.3. Hemagglutination test

[0243] The influenza virus or virus-like particles were diluted 2-fold with physiological saline or PBS, and 50 μl of each virus dilution was added to a 96-well U-bottom cell culture plate. 50 μl of 0.5% SPF chicken red blood cells were added to each well and mixed. After incubation at room temperature for about 30 minutes, the red blood cell agglutination phenomenon was observed, and the virus dilution that yielded one agglutination unit was the hemagglutination titer (HA titer).

[0244] 1.4. Preparation and detection of influenza virus pseudoviruses

[0245] 1.4.1. Preparation of influenza pseudovirus and control pseudovirus (calcium phosphate transfection method)

[0246] 9×10 cells were plated in a T75 cell culture flask (Thermo Fisher, Cat. No. 156499). 6 HEK293FT cells were cultured overnight, and 18 hours later, 15 ml of new culture medium was replaced with the cells, and 2 hours later, the transfection plasmid was added.

[0247] The plasmids for packaging pseudoviruses are four plasmid systems, including gene expression vector plasmid pCMV / R (used to express influenza virus HA and NA proteins as pseudovirus envelope proteins and vesicular stomatitis virus G protein (VSV-G) used as negative control), packaging vector plasmid pCMV / ΔR8.2 (used to express pseudovirus capsid protein) and transfer vector plasmid pHR'CMV-luc (used to express pseudovirus reporter gene protein). These four plasmids are assembled into pseudoviruses containing HA and NA proteins and control VSV-G pseudoviruses. The packaging vector plasmid and transfer vector plasmid were donated by Professor Luigi Naldini (University Torino Medical School, Torino, Italy). Plasmid structure as shown in Figure 2 shown.

[0248] The packaging system of influenza pseudovirus is:

[0249] 18.9 μg transfer vector plasmid pHR'CMV-Luc

[0250] 18.9 μg packaging vector plasmid pCMVΔR8.2

[0251] 2.7 μg hemagglutinin expression vector plasmid pCMV-HA

[0252] 0.675 μg neuraminidase expression vector plasmid pCMV-NA

[0253] 67.5 μl CaCl 2 (2.5M) solution

[0254] Add ddH 2 O to a volume of 675 μl, and then add 675 μl of 2×HEPES buffer (pH 7.10) dropwise, mixing by gently blowing with a pipette during the addition process.

[0255] The system of VSV-G control pseudovirus is:

[0256] 18.9 μg transfer vector plasmid pHR'CMV-Luc

[0257] 18.9 μg packaging vector plasmid pCMVΔR8.2

[0258] 2.7 μg VSV-G envelope plasmid pCMV-VSV-G

[0259] 67.5 μl CaCl 2 (2.5M) solution

[0260] Add ddH 2 O to a volume of 675 μl, and then add 675 μl of 2×HEPES buffer (pH 7.10) dropwise, mixing by gently blowing with a pipette during the addition process.

[0261] After standing at room temperature for about 20 minutes, the plasmid and calcium ions form a uniform precipitate, and the mixed liquid containing the precipitate is added dropwise and evenly to the HEK293FT cells. After 16-18 hours of cell culture, replace the fresh culture medium and add 100μM sodium butyrate for 6-8 hours, replace 15ml of fresh culture medium again and continue to culture for about 20 hours, and collect the supernatant containing pseudovirus. Centrifuge at 4000rpm for 5 minutes, remove possible cell residues, and filter with a 0.45μm filter (MilliporeMillex, catalog number SLHV033RB), and store the filtered pseudovirus supernatant at -80℃ for later use.

[0262] 1.4.2. Quantification of influenza pseudoviruses and control pseudoviruses

[0263] In the experiment, the relative luciferase activity (RLA) expressed by the transfer vector plasmid pHR'CMV-Luc after pseudovirus particles transduced MDCK cells was used as the detection standard for the pseudovirus infection ability of influenza virus. The method is as follows: MDCK cells were plated into 96-well flat-bottom cell culture plates, with 5,000 cells per well. After culturing for 20 hours, different volumes of pseudovirus supernatant to be tested were added, and the cells were incubated at 37°C and 5% CO 2 After 65 hours, the cell supernatant was discarded, and the cells were washed once with PBS and operated according to the instructions of the kit (Promega, Luciferase assay system freezer pack, catalog number E4530): 100 μl of cell lysis buffer was added, and 50 μl of luciferase reaction substrate was added after freeze-thawing to fully lyse the cells. The measured relative luciferase activity can intuitively indicate the infection titer of the pseudovirus to be tested.

[0264] 1.4.3. Construction of influenza pseudovirus library

[0265] The influenza pseudovirus library is used to detect the broad spectrum of immune serum, as shown in Table 6.

[0266] Table 6 Constructed H5 subtype influenza pseudovirus library

[0267] Virus strain Abbreviation Subclass Accession number A / Hong Kong / 156 / 1997 pHK156 0 AAC40508 A / Thailand / (KAN-1) / 2004 pTH 1 AAS65615 A / Cambodia / P0322095 / 2005 pCA 1 ADM95463 A / Indonesia / 5 / 2005 pID 2.1.3.2 ABP51969 A / Turkey / 65596 / 2006 pTK 2.2.1 ABQ58925 A / common magpie / Hong Kong / 5052 / 2007 pHK5052 2.3.2.1 ACJ26242 A / duck / Guangdong / S1322 / 2010(R6) pGD 2.3.2.1 A / Shenzhen / 406H / 2006 pSZ 2.3.4 ABO36644 A / chicken / Guizhou / 4 / 2013(R8) pGZ 2.3.4.4 A / Sichuan / 26221 / 2014 pSC 2.3.4.4 A / chicken / Netherland-14015526 / 2014 pNL 2.3.4.4 A / chicken / Guangxi / 12 / 2004 pGX12 2.4 ABD14809 A / chicken / Korea / es / 2003 pKR 2.5 ABP51986 A / silky chicken / Hong Kong / SF189 / 2001 pHKSF 3 AAO52864 A / goose / Guiyang / 337 / 2006 pGY 4 ABJ96698 A / duck / Guangxi / 1378 / 2004 pGX1378 5 ABC66526 A / blackbird / Hunan / 1 / 2004 pHN01 6 AAW19638 A / Duck / Hubei / wg / 2002 pHB 6 ABI94747 A / Beijing / 01 / 2003 Bj 7.1 ABQ58979 A / chicken / Shanxi / 2 / 2006 PcqI 7.2 ABK34764 A / chicken / Henan / 16 / 2004 pHN16 8 AAX53508 A / goose / Shantou / 1621 / 2005 pST 9 ABE68931

[0268] VSV-G pseudovirus was used as a control virus.

[0269] 1.5 Influenza pseudovirus neutralization experiment

[0270] The relative luciferase activity (RLA) expressed by the transfer vector plasmid pHR'CMV-Luc after the pseudovirus particles incubated with neutralizing antibodies or serum were used as the detection standard for the neutralization of the corresponding influenza virus pseudovirus by the neutralizing antibody or serum. The method is as follows: the serially diluted antibody or serum sample to be tested is mixed with an appropriate amount of the corresponding influenza virus pseudovirus and incubated at 37°C. After one hour, the above mixture is added to a 96-well cell culture plate pre-plated with MDCK cells and incubated at 37°C, 5% CO 2 After 65 hours, the cell supernatant was discarded, and the cells were washed once with PBS and operated according to the instructions of the kit (Promega, Luciferase assay system freezer pack, catalog number E4530): 100 μl of cell lysis solution was added, and 50 μl of luciferase reaction substrate was added after freeze-thawing to fully lyse the cells. The measured relative luciferase activity was used to calculate the titer of the neutralizing antibody or serum against the corresponding influenza virus pseudovirus, and the calculation formula was as follows:

[0271] Serum inhibition percentage = (relative luciferase value of pseudovirus in complete culture medium - relative luciferase value of pseudovirus in complete culture medium containing serially diluted antibodies) / relative luciferase value of pseudovirus in complete culture medium × 100%.

[0272] The indicator used to represent the serum neutralization titer in this study is the IC50 value, which refers to the serum dilution factor when the relative value of pseudovirus luciferase decreases by 50%. The IC50 value is calculated by fitting the serum dilution factor and the relative value of luciferase according to the Sigma curve using the software GraphPad Prism. The IC50 concentration is calculated by fitting the neutralization titer of the serially diluted antibody or serum sample according to the Sigma curve using the GraphPad Prism software.

[0273] 1.6 Preparation of DNA vaccines

[0274] Construction of pCMV / R vector plasmid: After mammalian codon optimization of the full-length sequence of hemagglutinin (including the transmembrane region and the intracellular region), a company (Nanjing GenScript Biotechnology Co., Ltd.) was commissioned to synthesize the full gene sequence and insert it into the pCMV / R vector (the constructed hemagglutinin DNA plasmid map is shown in Figure 3 coli (JM109) and cloned and amplified, the plasmid was extracted (QIAGEN, Cat. No. 12183) and identified (including: detection of plasmid concentration, determination of OD260 / 280 ratio, DNA agarose gel electrophoresis and plasmid sequencing). After the plasmid information was accurate, the plasmid was packaged and stored at -80°C for future use.

[0275] 1.7 Preparation of virus-like particle vaccines

[0276] 1.7.1 Packaging of Virus-Like Particles (VLP) (Calcium Phosphate Transfection Method)

[0277] 9×10 cells were plated in a T75 cell culture flask (Thermo Fisher, Cat. No. 156499). 6 HEK293FT cells were cultured for 18 hours and 15 ml of new culture medium was used to replace the cells. After 2 hours, the transfection plasmid was added.

[0278] The system of influenza virus-like particles is:

[0279] 18.9 μg packaging vector plasmid pCMVΔR8.2

[0280] 2.7 μg hemagglutinin expression vector plasmid pCMV-HA

[0281] 0.675 μg neuraminidase expression vector plasmid pCMV-NA

[0282] 67.5 μl CaCl 2 (2.5M) solution

[0283] Add ddH 2 O to a volume of 675 μl, and then add 675 μl of 2×HEPES buffer (pH 7.10) dropwise, mixing by gently blowing with a pipette during the addition process.

[0284] The control virus-like particle system is

[0285] 18.9 μg packaging vector plasmid pCMVΔR8.2

[0286] 2.7 μg VSV-G envelope plasmid pCMV-VSV-G

[0287] 67.5 μl CaCl 2 (2.5M) solution

[0288] Add ddH 2 O to a volume of 675 μl, and then add 675 μl of 2×HEPES buffer (pH 7.10) dropwise, mixing by gently blowing with a pipette during the addition process.

[0289] After the mixture was allowed to stand at room temperature for about 20 minutes, the plasmid and calcium ions formed a uniform precipitate, and the mixed precipitate was added dropwise and evenly to the HEK293FT cells. After 16-18 hours of cell culture, the fresh culture medium was replaced and 100 μM sodium butyrate was added for 6-8 hours. 15 ml of fresh culture medium was replaced again and culture was continued for about 20 hours, and the supernatant containing pseudovirus was collected. Centrifuge at 4000 rpm for 5 minutes, remove possible cell debris, and filter with a 0.45 μm filter (MilliporeMillex, SLHV033RB), and store the filtered pseudovirus supernatant at -80°C for later use.

[0290] 1.7.2 Concentration and purification of virus-like particles

[0291] After the collected virus-containing cell supernatant is centrifuged and filtered, centrifuge at 25,000rpm and 4℃ for 2 hours. Dissolve the VLP precipitate fully with PBS. Add the resuspended VLP to 30% and 45% (2 ml each) non-continuous sucrose density gradients. After centrifugation at 4℃ and 110,000xg for 3 hours, two turbid liquid bands (upper fuzzy band & lower fuzzy band) can be seen in the centrifuge tube. The upper fuzzy band is at the top of this gradient centrifuge tube, which mainly consists of Gag VLPs without envelope proteins on the surface and some small amounts of miscellaneous proteins; the lower fuzzy band is mainly VLPs with envelope spike proteins on the surface. Carefully remove the lower band, dilute it with PBS, and filter it with a 0.45μm filter membrane first, and then filter it with a 0.22μm filter membrane. The filtered VLP solution was added to a 20% sucrose cushion and centrifuged at 110,000 x g for 2 hours at 4°C. The VLP precipitate obtained by centrifugation was resuspended in sterile PBS, fully dissolved on ice, and then used to immunize experimental animals.

[0292] 1.7.3 Quantification of virus-like particles

[0293] Two methods are used to quantify virus-like particles: hemagglutination assay (only applicable to virus-like particles containing hemagglutinin protein) and enzyme-linked immunosorbent assay (ELISA). The method of hemagglutination assay is as described in 1.3, and is used to quantify the envelope protein on the surface of virus-like particles. The ELISA is used to quantify the matrix protein of virus-like particles. The specific steps are carried out according to the instructions of the HIV-1 antigen ELISA kit (ZeptoMetrix, catalog number 0801200). The specific process is as follows: Take out an appropriate amount of microwell strips of the HIV-1 P24 antigen ELISA kit, equilibrate and wash at room temperature, dilute the sample to be tested and the P24 protein standard with the diluent in the kit, take out 200 μl and add it to the microwell, then add 20 μl of lysis solution to each well, and incubate at 37°C for 4 hours (the P24 standard is diluted from 125 pg / ml to 7.8125 pg / ml and two replicate wells are tested. Two other wells are not added with the P24 standard as a negative control). After washing 6 times, add 100μl reconstituted HIV-1 P24 Detector Ab primary antibody to each well and incubate at 37℃ for one hour. After washing 6 times, add 100μl Streptavidin-Peroxidase working solution secondary antibody and incubate at 37℃ for 30 minutes. After washing 6 times, add 100μl Substrate working solution to each well, color at room temperature in the dark for 30 minutes, then add 100μl Stopbuffer to each well to terminate the reaction. Finally, take a wavelength of 450nm in the microplate reader and read the sample light absorption value (OD Value) within 15 minutes. Calculate the amount of P24 corresponding to the sample to be tested based on the standard curve drawn by the standard.

[0294] 1.8DDV immunization strategy

[0295] Female BALB / c mice aged 6-8 weeks were randomly divided into 6 groups and immunized on days 0, 21 and 42. The first and second immunizations were performed with DNA plasmids expressing HA protein, and 100 μg of plasmid was immunized in the hind limb muscle of each mouse. The third immunization was performed with surface membrane protein HA and NA virus-like particles (VLP), and 512 hemagglutination units were immunized in the peritoneal cavity of each mouse, as the DDV immunization group; the control group was immunized twice with empty plasmids, and 100 μg of plasmid was immunized in the hind limb muscle of each mouse. The booster immunization was performed with VLPs containing only HIV-1 gag, and each mouse was immunized in the peritoneal cavity.

[0296] 1.9 Experimental animal immunization and serum collection

[0297] The experimental animals for DDV immunization are mice. DDV immunization: The hemagglutinin nucleotide base sequence of the H5N1 subtype avian influenza virus strain A / common magpie / Hong Kong / 5052 / 2007 was inserted into the CMV / R vector to construct a plasmid, which was used to immunize mice. The hemagglutinin and neuraminidase of A / common magpie / Hong Kong / 5052 / 2007 were used as envelope proteins to prepare virus-like particles for booster immunization.

[0298] 1.10 Analysis of the broad spectrum, recognition epitopes and key amino acids of the A / common magpie / Hong Kong / 5052 / 2007 virus strain

[0299] 1.10.1 The neutralizing antibodies induced by the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007 have poor broad-spectrum

[0300] The present invention selects A / common magpie / Hong Kong / 5052 / 2007 hemagglutinin as a skeleton protein, firstly prepares immunogens with hemagglutinin and neuraminidase of A / common magpie / Hong Kong / 5052 / 2007 virus strain, randomly groups 6-8 week old female BALB / c mice, and immunizes them with DDV immunization strategy. 14 days after the last immunization, mouse immune serum is collected, and the broad spectrum of the immune serum is detected by pseudovirus neutralization experiment. The results in Table 7 show that the serum immunized with DDV has good neutralization activity against A / common magpie / Hong Kong / 5052 / 2007 virus strain, but has poor neutralization activity against other virus strains, and is a typical strain-specific immunogen.

[0301] Table 7. Broad spectrum of immunity of A / common magpie / Hong Kong / 5052 / 2007 virus strain

[0302]

[0303] (ND, Not Detected, Not Detected)

[0304] 1.10.2 The key amino acids recognized by neutralizing antibodies are concentrated in the amino acid hypervariable region at the outer edge of the hemagglutinin receptor binding region

[0305] In order to identify the epitopes and key amino acid sites recognized by the neutralizing antibodies induced by the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007, the present invention constructed a series of mutants. The spatial conformation of the hemagglutinin protein is divided into a head away from the transmembrane region and a rod close to the transmembrane region. The head contains four antibody binding regions, namely AS1, AS2, AS3 and AS4 (the spatial conformation of the hemagglutinin protein and the epitopes in the head region are as follows Figure 4 The neutralizing antibody induced by the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007 has high neutralizing activity against the virus strain A / common magpie / Hong Kong / 5052 / 2007, but low neutralizing activity against the virus strain A / Thailand / (KAN-1) / 2004. The recombinant protein immunogen was constructed by exchanging the amino acids in different regions of the hemagglutinin of these two virus strains, and a pseudovirus recombinant HA with the head and the stem exchanged was constructed (the schematic diagram of the construction of the recombinant HA with the head and the stem exchanged is shown in Figure 5 ), pseudoviruses with different epitope swaps ( Figure 6 ). This pseudovirus containing recombinant HA was used to detect changes in the neutralizing activity of immune serum and to infer the epitopes recognized by neutralizing antibodies and the locations of key amino acids.

[0306] First, in order to determine whether the neutralizing antibodies induced by the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007 are directed against the hemagglutinin head or the shaft, the present invention constructs a pseudovirus containing recombinant HA by exchanging the head and the shaft. The results in Table 8 show that the pseudovirus structure is complete and has hemagglutination activity, and the results in Table 9 show that exchanging the shaft will not affect the neutralizing titer of immune serum, exchanging the head can cause a significant change in the neutralizing titer of immune serum, and the neutralizing titer of the recombinant pseudovirus of HA with the same head and the wild-type pseudovirus is not significantly different, indicating that the neutralizing antibodies induced by the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007 are directed against the hemagglutinin head.

[0307] Table 8. Construction of HA pseudoviruses with recombinant head and stem

[0308]

[0309] Table 9. Comparison of neutralizing activity of neutralizing antibodies induced by DDV immunization strategy against HA recombinant pseudoviruses with swapped head and stem regions

[0310] Pseudovirus HK5052 DDV TH ND TH head / HK5052 stem ND HK5052 103,085 HK5052 head / TH stem 102,786

[0311] (ND, Not Detected, Not Detected)

[0312] The hemagglutinin head contains 4 antigenic epitopes (such as Figure 7 As shown in Table 10, in order to determine the specific epitope of the hemagglutinin head targeted by the neutralizing antibodies induced by the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007, the present invention constructs a HA recombinant pseudovirus with the head epitopes of A / common magpie / Hong Kong / 5052 / 2007 and A / Thailand / (KAN-1) / 2004 virus strains interchanged. The recombinant pseudovirus shown in Table 10 has a complete structure and hemagglutination activity, and can be used to analyze the specific epitopes recognized by immune serum. The results in Table 11 show that the interchange of AS2, AS3, AS4 and single point mutation of amino acid position 94 will not affect the neutralization titer of immune serum, the interchange of AS1 epitope can cause a significant change in the neutralization titer of immune serum, and the neutralization titer of the recombinant pseudovirus and the wild-type pseudovirus with the same AS1 epitope is not significantly different, indicating that the neutralizing antibodies induced by the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007 are targeted at the AS1 epitope of the hemagglutinin head.

[0313] Table 10. Name, hemagglutination titer, P24 content and ratio of the recombinant pseudovirus

[0314]

[0315] Table 11. Comparison of neutralizing activity of neutralizing antibodies induced by DDV immunization strategy against recombinant pseudoviruses with swapped head and stem regions

[0316] Pseudovirus HK5052 DDV Immunity TH ND THAS1HK5052 ND THAS2HK5052 93,809 THAS3HK5052 93,809 THAS4HK5052 98,912 THS94HK5052 97,943 HK5052 118,231 HK5052AS1TH 119,218 HK5052AS2TH ND HK5052AS3TH ND HK5052AS4TH ND HK5052S94TH ND

[0317] (ND, Not Detected, Not Detected)

[0318] In order to determine the key amino acids in the hemagglutinin AS1 epitope targeted by the neutralizing antibodies induced by the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007, the present invention compared the amino acid differences in the hemagglutinin AS1 epitope of the virus strains A / common magpie / Hong Kong / 5052 / 2007 and A / Thailand / (KAN-1) / 2004, and found that only 5 amino acids were different (such as Figure 7b), respectively located at amino acids 188 and 193 on the receptor binding site 190helix of the hemagglutinin protein and 158, 159, 160 on the outer edge loop of the receptor binding site. The mutant pseudovirus constructed by the present invention with these two positions interchanged is shown in Table 12, which can be used to analyze immune serum. The results in Table 13 show that swapping the amino acids at 190 helix does not affect the neutralization titer of the immune serum, while swapping 158, 159, and 160 at the outer edge loop of the receptor binding site can cause a significant change in the neutralization titer of the immune serum. The neutralization titer of the recombinant pseudovirus and the wild-type pseudovirus with the same amino acids at positions 158, 159, and 160 at the outer edge loop of the receptor binding site is not significantly different, indicating that the key amino acids induced by the neutralizing antibodies induced by the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007 are located at or near positions 158, 159, and 160. The amino acid conservation analysis of the hemagglutinin protein head found that the amino acids at or near positions 158, 159, and 160 of the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007 belong to the hypervariable region and are poorly conserved.

[0319] Table 12. Name, hemagglutination titer, P24 content and ratio of mutant pseudoviruses

[0320]

[0321] Table 13. Comparison of neutralizing activity of neutralizing antibodies induced by DDV immunization against mutant pseudoviruses

[0322] Pseudovirus HK5052 DDV Immunity TH ND THA188EK193R ND THN158GS159NT160A 97,342 HK5052 109,345 HK5052E188AR193K 94,573 HK5052G158NN159SA160T ND

[0323] (ND, Not Detected, Not Detected)

[0324] Positions 158, 159 and 160 are located at the outer edge of the head receptor binding site of the hemagglutinin protein. Positions 158, 159 and 160 and their vicinity are amino acid hypervariable regions ( Figure 8 ).

[0325] 1.10.3 Preparation of broad-spectrum influenza vaccine against H5N6 subtype

[0326] The hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007 was used as the backbone protein, the AS1 epitope of the A / Sichuan / 26221 / 2014 virus strain was transferred to the hemagglutinin of A / common magpie / Hong Kong / 5052 / 2007, and the aspartic acid (Asp, D) and alanine (Ala, A) at positions 159 and 160 of the AS1 epitope were mutated to serine (Ser, S) and threonine (Thr, T), and N-sugar chains were introduced into the hypervariable region at the outer edge of the receptor binding site. The HA recombinant immunogen was constructed and named SCAS1HK5052 (SEQ ID NO.: 1). Mice were immunized by "DDV" immunization method, and mouse serum was collected 14 days after the last immunization to analyze the broad spectrum of the immune serum.

[0327] The results in Table 14 show that the neutralizing antibodies induced by the constructed HA recombinant immunogen SCAS1HK5052 "DDV" immunization can neutralize 21 representative pseudovirus strains except A / chicken / Shanxi / 2 / 2006 pseudovirus, and the broad spectrum is very good, while the neutralizing antibodies induced by the wild virus strain (A / Sichuan / 26221 / 2014) "DDV" immunization can only neutralize 8 representative pseudovirus strains, and no neutralizing effect was detected for the remaining 14 pseudovirus strains, and the broad spectrum is poor. The results show that the H5N6 mutant vaccine strain prepared by the present invention can neutralize most of the representative strains of 10 subtypes of the H5 subtype (taking the viruses prevalent between 1997 and 2014 as an example), and has a good broad spectrum.

[0328] Table 14. Broad spectrum analysis of sera immune to A / Sichuan / 26221 / 2014 and mutant vaccine strains DDV

[0329]

[0330]

[0331] (ND, Not Detected, Not Detected)

[0332] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application. Sequence Listing <110> Nanjing Institute of Advanced Life Sciences, Chinese Academy of Sciences <120> Development and application of a broad-spectrum vaccine against H5N6 avian influenza <130> P2022-1140 <160> 3 <170> PatentIn version 3.5 <210> 1 <211> 567 <212> PRT <213> Artificial sequence <400> 1 Met Glu Lys Ile Val Leu Leu Phe Ala Ile Val Ser Leu Val Lys Ser 1 5 10 15 Asp His Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val 20 25 30 Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile 35 40 45 Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asn Gly Val Lys 50 55 60 Pro Leu Ile Leu Lys Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80 Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val 85 90 95 Glu Lys Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn 100 105 110 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu 115 120 125 Lys Ile Gln Ile Ile Pro Lys Asp Ser Trp Ser Asn His Glu Thr Ser 130 135 140 Leu Gly Val Ser Ala Ala Cys Pro Tyr Gln Gly Asn Ser Ser Phe Phe 145 150 155 160 Arg Asn Val Val Trp Leu Ile Lys Lys Asn Ser Thr Tyr Pro Thr Ile 165 170 175 Lys Lys Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp 180 185 190 Gly Ile His His Pro Asn Asn Ala Ala Glu Gln Thr Asn Leu Tyr Gln 195 200 205 Asn Pro Thr Thr Tyr Ile Ser Ile Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220 Leu Val Pro Lys Ile Ala Thr Arg Ser Gln Val Asn Gly Gln Arg Gly 225 230 235 240 Arg Ile Asp Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn 245 250 255 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 260 265 270 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Val Glu Tyr Gly 275 280 285 Asn Cys Asn Thr Arg Cys Gln Thr Pro Met Gly Ala Ile Asn Ser Ser 290 295 300 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320 Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335 Pro Gln Arg Glu Arg Arg Arg Lys Arg Gly Leu Phe Gly Ala Ile Ala 340 345 350 Gly Phe Ile Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly 355 360 365 Tyr His His Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu 370 375 380 Ser Thr Gln Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile 385 390 395 400 Ile Asp Lys Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn 405 410 415 Asn Leu Glu Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp Gly 420 425 430 Phe Leu Asp Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu 435 440 445 Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr 450 455 460 Asp Lys Val Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly Asn 465 470 475 480 Gly Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser 485 490 495 Val Arg Asn Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg 500 505 510 Leu Lys Arg Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Thr 515 520 525 Tyr Gln Ile Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu 530 535 540 Ala Ile Met Val Ala Gly Leu Ser Ser Trp Met Cys Ser Asn Gly Ser 545 550 555 560 Leu Gln Cys Arg Ile Cys Ile 565 <210> 2 <211> 568 <212> PRT <213> Artificial sequence <400> 2 Met Glu Lys Ile Val Phe Leu Leu Ala Ile Val Ser Leu Val Lys Ser 1 5 10 15 Asp His Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val 20 25 30 Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile 35 40 45 Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asn Gly Val Lys 50 55 60 Pro Leu Ile Leu Lys Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80 Pro Met Cys Asp Glu Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val 85 90 95 Glu Lys Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Phe Asn 100 105 110 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu 115 120 125 Lys Ile Gln Ile Ile Pro Lys Asp Ser Trp Ser Asp His Glu Ala Ser 130 135 140 Leu Gly Val Ser Ser Ala Cys Pro Tyr Gln Gly Asn Ser Ser Phe Phe 145 150 155 160 Arg Asn Val Val Trp Leu Ile Lys Lys Gly Asn Ala Tyr Pro Thr Ile 165 170 175 Lys Lys Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Val Leu Trp 180 185 190 Gly Ile His His Pro Asn Asp Glu Ala Glu Gln Thr Arg Leu Tyr Gln 195 200 205 Asn Pro Thr Thr Tyr Ile Ser Ile Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220 Leu Val Pro Lys Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly 225 230 235 240 Arg Ile Asp Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn 245 250 255 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 260 265 270 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Val Glu Tyr Gly 275 280 285 Asn Cys Asn Thr Arg Cys Gln Thr Pro Met Gly Ala Ile Asn Ser Ser 290 295 300 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320 Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335 Pro Gln Arg Glu Arg Arg Arg Lys Lys Arg Gly Leu Phe Gly Ala Ile 340 345 350 Ala Gly Phe Ile Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr 355 360 365 Gly Tyr His His Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys 370 375 380 Glu Ser Thr Gln Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser 385 390 395 400 Ile Ile Asp Lys Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe 405 410 415 Asn Asn Leu Glu Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp 420 425 430 Gly Phe Leu Asp Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met 435 440 445 Glu Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu 450 455 460 Tyr Asp Lys Val Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly 465 470 475 480 Asn Gly Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu 485 490 495 Ser Val Arg Asn Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala 500 505 510 Arg Leu Lys Arg Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly 515 520 525 Thr Tyr Gln Ile Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Val 530 535 540 Leu Ala Ile Met Val Ala Gly Leu Ser Ser Trp Met Cys Ser Asn Gly 545 550 555 560 Ser Leu Gln Cys Arg Ile Cys Ile 565 <210> 3 <211> 567 <212> PRT <213> artificial sequence <400> 3 Met Glu Lys Ile Val Leu Leu Leu Ala Ile Val Ser Leu Val Lys Gly 1 5 10 15 Asp Gln Ile Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val 20 25 30 Asp Thr Ile Met Glu Lys Asn Val Thr Val Thr His Ala Gln Asp Ile 35 40 45 Leu Glu Lys Thr His Asn Gly Lys Leu Cys Asp Leu Asn Gly Val Lys 50 55 60 Pro Leu Ile Leu Lys Asp Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 65 70 75 80 Pro Met Cys Asp Glu Phe Ile Arg Val Pro Glu Trp Ser Tyr Ile Val 85 90 95 Glu Arg Ala Asn Pro Ala Asn Asp Leu Cys Tyr Pro Gly Asn Leu Asn 100 105 110 Asp Tyr Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu 115 120 125 Lys Ile Leu Ile Ile Pro Lys Ser Ser Trp Thr Asn His Glu Thr Ser 130 135 140 Leu Gly Val Ser Ala Ala Cys Pro Tyr Gln Gly Thr Pro Ser Phe Phe 145 150 155 160 Arg Asn Val Val Trp Leu Ile Lys Lys Asn Asp Ala Tyr Pro Thr Ile 165 170 175 Lys Ile Ser Tyr Asn Asn Thr Asn Gln Glu Asp Leu Leu Ile Leu Trp 180 185 190 Gly Val His His Ser Asn Asn Ala Ala Glu Gln Thr Asn Leu Tyr Lys 195 200 205 Asn Pro Thr Thr Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg 210 215 220 Leu Val Pro Lys Ile Ala Thr Arg Ser Gln Val Asn Gly Gln Arg Gly 225 230 235 240 Arg Met Asp Phe Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile His 245 250 255 Phe Glu Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 260 265 270 Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Met Glu Tyr Gly 275 280 285 His Cys Asn Thr Lys Cys Gln Thr Pro Ile Gly Ala Ile Asn Ser Ser 290 295 300 Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly Glu Cys Pro Lys 305 310 315 320 Tyr Val Lys Ser Asn Lys Leu Val Leu Ala Thr Gly Leu Arg Asn Ser 325 330 335 Pro Leu Arg Glu Lys Arg Arg Lys Arg Gly Leu Phe Gly Ala Ile Ala 340 345 350 Gly Phe Ile Glu Gly Gly Trp Gln Gly Met Val Asp Gly Trp Tyr Gly 355 360 365 Tyr His His Ser Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Lys Glu 370 375 380 Ser Thr Gln Lys Ala Ile Asp Gly Val Thr Asn Lys Val Asn Ser Ile 385 390 395 400 Ile Asp Lys Met Asn Thr Gln Phe Glu Ala Val Gly Arg Glu Phe Asn 405 410 415 Asn Leu Glu Arg Arg Ile Glu Asn Leu Asn Lys Lys Met Glu Asp Gly 420 425 430 Phe Leu Asp Val Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Met Glu 435 440 445 Asn Glu Arg Thr Leu Asp Phe His Asp Ser Asn Val Lys Asn Leu Tyr 450 455 460 Asp Lys Val Arg Leu Gln Leu Arg Asp Asn Ala Lys Glu Leu Gly Asn 465 470 475 480 Gly Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Lys Cys Met Glu Ser 485 490 495 Val Arg Asn Gly Thr Tyr Asp Tyr Pro Gln Tyr Ser Glu Glu Ala Arg 500 505 510 Leu Lys Arg Glu Glu Ile Ser Gly Val Lys Leu Glu Ser Ile Gly Thr 515 520 525 Tyr Gln Ile Leu Ser Ile Tyr Ser Thr Val Ala Ser Ser Leu Ala Leu 530 535 540 Ala Ile Ile Val Ala Gly Leu Ser Leu Trp Met Cys Ser Asn Gly Ser 545 550 555 560 Leu Gln Cys Arg Ile Cys Ile 565

Claims

1. A hemagglutinin recombinant protein, characterized in that: The amino acid sequence of the recombinant protein is shown in SEQ ID NO.

1.

2. A vaccine polypeptide, characterized in that: The vaccine polypeptide comprises the recombinant protein according to claim 1.

3. A DNA or mRNA vaccine, characterized in that: The vaccine contains mRNA encoding the recombinant protein according to claim 1 and a DNA expression vector.

4. An isolated polynucleotide, characterized in that The polynucleotide encodes the recombinant protein according to claim 1 or the vaccine polypeptide according to claim 2.

5. An expression vector, characterized in that: The expression vector contains the polynucleotide according to claim 4.

6. A host cell, characterized in that The host cell contains the expression vector according to claim 5, or the polynucleotide according to claim 4 is integrated into its genome.

7. An H5 subtype influenza virus strain, characterized in that The genome of the virus strain contains an exogenous recombinant protein gene sequence, wherein the recombinant protein gene sequence encodes the hemagglutinin recombinant protein according to claim 1.

8. A pharmaceutical composition, characterized in that The composition contains the recombinant protein according to claim 1, the vaccine polypeptide according to claim 2, the mRNA or DNA vaccine according to claim 3, the polynucleotide according to claim 4, the expression vector according to claim 5, the host cell according to claim 6, or the virus strain according to claim 7, and a pharmaceutically acceptable carrier and / or excipient.

9. A vaccine composition, characterized in that The composition contains the recombinant protein according to claim 1, the vaccine polypeptide according to claim 2, the mRNA or DNA vaccine according to claim 3, the polynucleotide according to claim 4, the expression vector according to claim 5, the host cell according to claim 6, or the virus strain according to claim 7, and an immunologically acceptable carrier and / or adjuvant.

10. Use of the recombinant protein according to claim 1, the vaccine polypeptide according to claim 2, the mRNA or DNA vaccine according to claim 3, the virus strain according to claim 7, the pharmaceutical composition according to claim 8, or the vaccine composition according to claim 9, characterized in that: (a) for preparing antibodies against avian influenza virus hemagglutinin; and / or (b) for preparing drugs for preventing and / or treating avian influenza virus infection, wherein the avian influenza virus includes H5 subtype avian influenza virus.